Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28150049 | 0.89 | CA12 (0.50) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL29800427 | 0.81 | CA12 (0.56) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL659139 | 0.81 | CA12 (0.56) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL811649 | 0.81 | CA12 (0.56) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL152572 | 0.79 | CA12 (0.59) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL30893690 | 0.79 | CA12 (0.59) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL29637478 | 0.79 | MAPK1 (0.61) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1971939 | 0.79 | MAPK1 (0.61) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL465881 | 0.78 | LMNA (0.61) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6087503 | 0.78 | CA12 (0.53) | HPGDCYP1A2CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193060-A1 | Inhibition of IL-1 Induced Inflammation | THIOLAB LLC (US) | 2022-06-23 | — | — | US | claimed |
| WO-2020223608-A1 | INHIBITION OF IL-1 AND IL-6 INFLAMMATION | THIOLAB, LLC, (US) | 2020-11-05 | — | — | WO | claimed |
| EP-1383499-B1 | METHOD OF IMMUNOMODULATION USING THIONE-FORMING DISULFIDES | GRASSETTI FAMILY TRUST (US) | 2013-03-06 | — | — | EP | claimed |
| US-8163776-B2 | Immunomodulation by administering thione-forming dithiobis-heterocyclic compound, increased natural killer cell activity, expansion of NK cell population, decreased B cell population, decreased antibody production | GRASSETTI FAMILY TRUST (US) | 2012-04-24 | — | — | US | claimed |
| US-20040265327-A1 | Method of immunomodulation using thione-forming disulfides | GRASSETTI, DAVIDE | 2004-12-30 | — | — | US | claimed |
| EP-1383499-A2 | METHOD OF IMMUNOMODULATION USING THIONE-FORMING DISULFIDES | Grassetti, Davide R. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002055080-A2 | METHOD OF IMMUNOMODULATION USING THIONE-FORMING DISULFIDES | GRASSETTI DAVIDE R (US) | 2002-07-18 | — | — | WO | claimed |
| US-20220193060-A1 | Inhibition of IL-1 Induced Inflammation | THIOLAB LLC (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2020223608-A1 | INHIBITION OF IL-1 AND IL-6 INFLAMMATION | THIOLAB, LLC, (US) | 2020-11-05 | — | — | WO | disclosed |
| EP-1383499-B1 | METHOD OF IMMUNOMODULATION USING THIONE-FORMING DISULFIDES | GRASSETTI FAMILY TRUST (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8163776-B2 | Immunomodulation by administering thione-forming dithiobis-heterocyclic compound, increased natural killer cell activity, expansion of NK cell population, decreased B cell population, decreased antibody production | GRASSETTI FAMILY TRUST (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163776-B2 | Immunomodulation by administering thione-forming dithiobis-heterocyclic compound, increased natural killer cell activity, expansion of NK cell population, decreased B cell population, decreased antibody production | GRASSETTI FAMILY TRUST (US) | 2012-04-24 | — | — | US | disclosed |
| US-20040265327-A1 | Method of immunomodulation using thione-forming disulfides | GRASSETTI, DAVIDE | 2004-12-30 | — | — | US | disclosed |
| EP-1383499-A2 | METHOD OF IMMUNOMODULATION USING THIONE-FORMING DISULFIDES | Grassetti, Davide R. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002055080-A2 | METHOD OF IMMUNOMODULATION USING THIONE-FORMING DISULFIDES | GRASSETTI DAVIDE R (US) | 2002-07-18 | — | — | WO | disclosed |
| US-4378364-A | DITHIOBIS(PYRIDINE-CARBOXYLIC ACID) TO RELIEVE PAIN, INCREASE APPETITE | GRASSETTI DAVIDE R | 1983-03-29 | — | — | US | disclosed |
| US-4152439-A | 6,6-DITHIODINICOTINIC ACID, ESTER OR ALKALI METAL OR AMMONIUM SALT | Grassetti, Davide R. (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265327-A1 | Method of immunomodulation using thione-forming disulfides | TST, PBK, ICOS | HPGD 185/4885CYP1A2 2536/4885CYP2C9 2140/4885 |
| US-20220193060-A1 | Inhibition of IL-1 Induced Inflammation | IL1B, IL1A, IL6 | HPGD 461/4885CYP1A2 1382/4885CYP2C9 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.